The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.
 
Francois Clement Bidard
Consulting or Advisory Role - AstraZeneca; Carrick Pharm; Daiichi-Sankyo; Hengrui Pharmaceutical ; Inatherys; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Relay Tx; Roche; Tempus
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Roche
Research Funding - GE Healthcare (Inst); Menarini Silicon Biosystems (Inst); Merck KGaA (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); Personalis (Inst); Pfizer (Inst); Prolynx (Inst); Roche (Inst); SAGA Dx (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - ESR1 & MSI detection techniques (patents) (Inst); Prognosis assessment by a digital pathology assay in early breast cancer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Novartis; Pfizer; Roche
 
Erica Mayer
Consulting or Advisory Role - AstraZeneca; Atkis; Genentech; Lilly; Novartis
 
Yeon Hee Park
Honoraria - AimedBio; AstraZeneca; BeOne; BMS; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Healthcare; Lilly; MSD; Novartis; Pfizer; Roche; Voronoi Health Analytics
Consulting or Advisory Role - AimedBio; AstraZeneca; BMS; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Therapeutics; Jazz Pharmaceuticals; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Voronoi Health Analytics
Research Funding - AstraZeneca; Boryung; Daewoong Pharmaceutical; Gencurix; Gencurix (Inst); Gilead Sciences; Inocras; Inocras (Inst); Kirin Pharmaceuticals; NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilad; Helsinn Therapeutics; Jazz Pharmaceuticals; Novartis; Pfizer; Roche
 
Wolfgang Janni
No Relationships to Disclose
 
Cynthia Ma
Consulting or Advisory Role - AstraZeneca; Bayer; Biovica; Daiichi Sankyo/Astra Zeneca; Delphi Diagnostics; FoRx; Foundation Medicine; Lilly; Merck; Novartis; Olaris; Pathlight; Pfizer; Puma Biotechnology; Regor Therapeutics Group; Stemline Therapeutics; Stemline Therapeutics; Tempus
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate: Authorship - served as a co-author on the subject of endocrine therapy for metastatic breast cancer and receive compensation as an author, less than a few hundred dollars a year. It does not affect my patient care or research.
 
Massimo Cristofanilli
Honoraria - AstraZeneca; Datar Cancer Genetics; Guardant Health; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Menarini
Research Funding - Angle; AstraZeneca; Lilly; Menarini Silicon Biosystems; Merck
 
Giampaolo Bianchini
Honoraria - AstraZeneca/Daiichi Sankyo; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo Europe GmbH; Exact Sciences; Gilead Sciences; Helsinn Therapeutics; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - AstraZeneca; Lilly; MSD; Novartis
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Menarini; Novartis; Pfizer; Roche; Takeda
 
Kevin Kalinsky
Employment - ADC Therapeutics (I); EQRx (I)
Stock and Other Ownership Interests - ADC Therapeutics (I); EQRx (I)
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; bioTheranostics; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Gilead Sciences; Lilly; Menarini Silicon Biosystems; Merck; mersana; Mersana; Novartis; Pfizer; ProteinQure; Puma Biotechnology; Regor; Relay Therapeutics
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Gilead Sciences; Lilly Japan; MSD; Myriad Genetics; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; CMIC Co., Ltd.; Daiichi Sankyo; Gilead Sciences; Lilly Japan; MSD; Pfizer
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst)
 
Stephen Chia
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Ataraxis; Celcuity; Daiichi Sankyo/Lilly; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer; Sanofi
 
Peter Fasching
Honoraria - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; SeaGen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Guardant Health; Hexal; Lilly; Menarini Group; Merck Sharp & Dohme; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Pfizer (Inst); Roche
 
Zbigniew Nowecki
Travel, Accommodations, Expenses - Roche/Genentech
 
Javier Pascual
Honoraria - AstraZeneca; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly; Menarini; MSD Oncology; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Nuri Karadurmus
No Relationships to Disclose
 
Einav Gal-Yam
Honoraria - AstraZeneca; Lilly; msd; Pfizer; Roche; Sermonix Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; roche
Travel, Accommodations, Expenses - Gilead Sciences (Inst); msd; Pfizer (Inst); Roche
 
Arkendu Chatterjee
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Manuel Selvi Miralles
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Cynthia Bartlett
Employment - AstraZeneca; Merck; Pfizer
Stock and Other Ownership Interests - AstraZeneca; Pfizer
 
Nicholas Turner
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Guardant Health; Inivata; Lilly; Novartis; Pfizer; Relay Therapeutics; Repare Therapeutics; Roche/Genentech
Research Funding - AstraZeneca (Inst); Guardant Health (Inst); Inivata (Inst); Invitae (Inst); MSD (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Bio-Rad (Inst)